Patents by Inventor Jeng-Jong Hwang

Jeng-Jong Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition and Use of Interleukin Stimulated Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Rheumatoid Arthritis
    Publication number: 20220152121
    Abstract: The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1?, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis.
    Type: Application
    Filed: June 8, 2021
    Publication date: May 19, 2022
    Inventors: Hwai-Shi WANG, Jeng-Jong HWANG
  • Liposomal lupeol acetate and the use thereof in preparing drugs for rheumatoid arthritis
    Patent number: 10441540
    Abstract: The present invention relates to a liposomal lupeol acetate (Lipo-LA) and its use in the treatment or prevention of rheumatoid arthritis (RA). The liposomal lupeol acetate of the present invention especially inhibits inflammatory responses and osteoclast generation (osteoclastogenesis) in the progression of rheumatoid arthritis (RA) at a half dose of the un-capsulated lupeol acetate, which may significantly reduce the incidence of RA and improve the therapeutic efficacy of lupeol acetate.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 15, 2019
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Jeng-Jong Hwang, Wei-Hsun Wang
  • COMBINATION OF LUPEOL ACETATE AND CURCUMIN USED FOR THE TREATMENT OR PREVENTION OF OSTEOPOROSIS
    Publication number: 20170312294
    Abstract: The present invention relates to synergistic combinations of lupeol acetate and curcumin at low dosage, and their use for the treatment or prevention of osteoporosis.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Inventors: Jeng-Jong HWANG, Wei-Hsun WANG
  • COMBINATION OF LUPEOL ACETATE AND CURCUMIN USED FOR THE TREATMENT OR PREVENTION OF ACTIVATED OSTEOCLAST PRECURSOR ASSOCIATED DISORDERS
    Publication number: 20160220582
    Abstract: The present invention relates to synergistic combinations of lupeol acetate and curcumin at low dosage, and their use for the treatment or prevention of activated osteoclast precursor related diseases, including rheumatoid arthritis and osteoporosis.
    Type: Application
    Filed: September 11, 2015
    Publication date: August 4, 2016
    Inventors: Jeng-Jong HWANG, Wei-Hsun WANG
  • LIPOSOMAL LUPEOL ACETATE AND THE USE THEREOF IN PREPARING DRUGS FOR RHEUMATOID ARTHRITIS
    Publication number: 20150258025
    Abstract: The present invention relates to a liposomal lupeol acetate (Lipo-LA) and its use in the treatment or prevention of rheumatoid arthritis (RA). The liposomal lupeol acetate of the present invention especially inhibits inflammatory responses and osteoclast generation (osteoclastogenesis) in the progression of rheumatoid arthritis (RA) at a half dose of the un-capsulated lupeol acetate, which may significantly reduce the incidence of RA and improve the therapeutic efficacy of lupeol acetate.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 17, 2015
    Inventors: Jeng-Jong HWANG, Wei-Hsun WANG
  • METHOD OF USING AN ANTIDEPRESSANT FOR INCREASING IMMUNITY OF A SUBJECT AND TREATING CANCER
    Publication number: 20140271727
    Abstract: A method of increasing immunity of a subject by administering an antidepressant to the subject is disclosed in the present invention. Preferably, the antidepressant is mirtazapine. And further, another object of the present invention is related to a method of administering the abovementioned antidepressant to the subject for treating cancer. The present invention tries to find the mechanism of the tumor growth inhibition by mirtazapine, and it may be due to the alteration of the tumor microenvironment, which involves the activation of the immune response and the recovery of serotonin level.
    Type: Application
    Filed: March 18, 2013
    Publication date: September 18, 2014
    Inventors: Jeng-Jong Hwang, Chun-Kai Fang
  • LIPOSOME COMPOSITIONS USEFUL FOR TUMOR IMAGING AND TREATMENT
    Publication number: 20090081121
    Abstract: The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject.
    Type: Application
    Filed: September 25, 2008
    Publication date: March 26, 2009
    Applicants: National Health Research Institute, National Yang Ming University, Taiwan Liposome Company, Ltd.
    Inventors: Gann Ting, Yun-Long Tseng, Jun-Jen Liu, Hsin-Ell Wang, Jeng-Jong Hwang, Yi-Ching Lu, Wan-Chi Lee